BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 870189)

  • 1. The prevention of methotrexate toxicity by thymidine infusions in humans.
    Ensminger WD; Frei E
    Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidine rescue of high-dose methotrexate in humans.
    Howell SB; Ensminger WD; Krishan A; Frei E
    Cancer Res; 1978 Feb; 38(2):325-30. PubMed ID: 637906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
    Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
    Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.
    Benz C; DeGregorio M; Saks S; Sambol N; Holleran W; Ignoffo R; Lewis B; Cadman E
    Cancer Res; 1985 Jul; 45(7):3354-8. PubMed ID: 4005858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacologic effects of thymidine plus 5-FU.
    Ohnuma T; Roboz J; Waxman S; Mandel E; Martin DS; Holland JF
    Cancer Treat Rep; 1980; 64(12):1169-77. PubMed ID: 7471111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study.
    Dady PJ; Taylor GA; Muindi JF; Calvert AH; Smith IE; Smyth JF; Harrap KR
    Cancer Treat Rep; 1981; 65 Suppl 1():37-43. PubMed ID: 7326664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.
    Kirkwood JM; Ensminger W; Rosowsky A; Papathanasopoulos N; Frei E
    Cancer Res; 1980 Jan; 40(1):107-13. PubMed ID: 7349890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
    Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
    Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
    Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
    Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
    Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
    J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Severe renal impairment of methotrexate elimination after high dose therapy].
    Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
    Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.
    Pinedo HM; Zaharko DS; Bull J; Chabner BA
    Cancer Res; 1977 Feb; 37(2):445-50. PubMed ID: 832268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate.
    Howell SB; Krishan A; Frei E
    Cancer Res; 1979 Apr; 39(4):1315-20. PubMed ID: 311245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study.
    Parker LM; Griffiths CT; Yankee RA; Knapp RC; Canellos GP
    Cancer Treat Rep; 1979 Feb; 63(2):275-9. PubMed ID: 312692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma].
    Sampi K; Hattori M
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):1068-73. PubMed ID: 6985194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic studies during phase I trials of high-dose thymidine infusions.
    Zaharko DS; Bolten BJ; Chiuten D; Wiernik PH
    Cancer Res; 1979 Dec; 39(12):4777-81. PubMed ID: 498107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.